210 related articles for article (PubMed ID: 33890520)
1. Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
van Lierop ZY; Wieske L; Koel-Simmelink MJ; Chatterjee M; Dekker I; Leurs CE; Willemse EA; Moraal B; Barkhof F; Eftimov F; Uitdehaag BM; Killestein J; Teunissen CE
Mult Scler; 2022 Jan; 28(1):102-110. PubMed ID: 33890520
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY; Noteboom S; Steenwijk MD; van Dam M; Toorop AA; van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Teunissen CE; Killestein J
Mult Scler; 2022 Dec; 28(14):2231-2242. PubMed ID: 36062492
[TBL] [Abstract][Full Text] [Related]
3. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
6. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
[TBL] [Abstract][Full Text] [Related]
9. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
13. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.
Pato Pato A; Costa Arpín E; Rodríguez Regal A; Rodríguez Constenla I; Cimas Hernando I; Muñoz Pousa I; Naya Ríos L; Lorenzo González JR; Amigo Jorrín MC; Prieto González JM
Neurologia (Engl Ed); 2021 Jun; 36(5):346-352. PubMed ID: 34714232
[TBL] [Abstract][Full Text] [Related]
14. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K; Fabacher T; Kremer L; Ongagna JC; Kwiatkowski A; Sellal F; Ferriby D; Courtois S; Vermersch P; Collongues N; Zéphir H; De Seze J; Outteryck O
Mult Scler; 2021 Apr; 27(5):729-741. PubMed ID: 32643521
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
18. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
19. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
[TBL] [Abstract][Full Text] [Related]
20. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
